Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmunomeIMNM +2.00%43 3-1 Month Momentum % is 51.87% as of Sep. 17, 2026. GuruFocus rates IMNM with a GF Score™ of 43/100 and a GF Value™ of $1.01 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,385 Biotechnology companies, Immunome ranks better than 93.29% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-17), Immunome's 3-1 Month Momentum % is 51.87%.
The industry rank for Immunome's 3-1 Month Momentum % or its related term are showing as below:
IMNM's 3-1 Month Momentum % is ranked better than 93.29% of 1385
companies
in the Biotechnology industry
Industry Median: 1.6
vs IMNM: 51.87
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Immunome 3-1 Month Momentum % Related Terms
IMNM vs TARS, NAMS, IRON: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Immunome's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunome 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunome's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Immunome's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunome (IMNM) has a 3-1 Month Momentum % of 51.87% as of Sep. 17, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Immunome and its competitors. According to the industry distribution chart, Immunome ranks #93 out of 1385 companies in the Biotechnology industry, placing it in the top 6.7%.
Is Immunome's 3-1 Month Momentum % too high?
Immunome's current 3-1 Month Momentum % is 51.87%. The Biotechnology industry median 3-1 Month Momentum % is 1.60. Immunome's value of 51.87% is 3141.9% above this industry median. Based on the distribution chart, Immunome ranks #93 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immunome has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immunome's 3-1 Month Momentum % compare to TARS and NAMS?
According to the Biotechnology industry distribution chart, Immunome ranks #93 out of 1385 companies for 3-1 Month Momentum %. This places Immunome in the top 7% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 1.60. Immunome's value of 51.87% is 3141.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.60, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunome's current 3-1 Month Momentum % of 51.87% is 3141.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Immunome and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunome's current 3-1 Month Momentum % is 51.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunome stock overvalued right now?
Based on GuruFocus' analysis, Immunome (IMNM) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.01, compared to a current price of $23.93 — trading 2269.3% above its estimated fair value. The current 3-1 Month Momentum % is 51.87% and 3141.9% above the Biotechnology industry median of 1.60. Immunome's overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Immunome (IMNM), the current 3-1 Month Momentum % is 51.87% as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunome (IMNM) Overvalued in 2026?
Based on GuruFocus' analysis, Immunome stock appears to be overvalued.
The current stock price of $23.93 is trading 2269.3% above its estimated GF Value™ of $1.01.
GuruFocus considers Immunome to be Significantly Overvalued.
Key valuation signals for IMNM:
3-1 Month Momentum %: 51.87%
GF Value™: $1.01 vs. price of $23.93 (2269.3% above fair value)
Industry Position: 3141.9% above the Biotechnology median (#93 of 1385)
No single metric tells the full story. See the IMNM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
43GF Score
Get the complete analysis for IMNM
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMNM has been successfully added to your 
